The viral Macrophage Inflammatory Protein-II (vMIP-II) is a chemokine that interacts with the CC and CXC chemokine receptors, including the CCR5 and CXCR4 chemokine receptors. CCR5 and CXCR4 are the principal coreceptors required for cell entry of human immunodeficiency virus type 1 (HIV-1). The present invention describes a peptide fragment of the vMIP-II that prevents the HIV-1 virus from interacting with the coreceptor CXCR4, thereby preventing viral infection of that cell. These peptide fragments will serve as lead compounds for the development of therapeutic agents against HIV-1 infections.
病毒性巨噬细胞炎症蛋白-II(vMIP-II)是一种与 CC 和 CXC
趋化因子受体(包括 CCR5 和 CXCR4
趋化因子受体)相互作用的
趋化因子。CCR5 和 CXCR4 是人类免疫缺陷病毒 1 型(HIV-1)进入细胞所需的主要核心受体。本发明描述了一种 vMIP-II 肽片段,它能阻止 HIV-1 病毒与核心受体 CXCR4 相互作用,从而防止病毒感染该细胞。这些肽片段将作为先导化合物,用于开发抗 HIV-1 感染的治疗药物。